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A B S T R A C T
Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into uterine leio-
myosarcoma (uLMS), low grade endometrial stromal sarcoma (LG-ESS), high grade endometrial stromal sarcoma
(HG-ESS), adenosarcomas and high grade undiﬀerentiated sarcoma (HGUS). US are often high-grade tumours
with a high local recurrence rate and metastatic risk. We here discuss the current standard of care and knowledge
of systemic therapy for adult uterine sarcomas, in particular uLMS, LG-ESS, HG-ESS and HGUS, in both the
adjuvant as well as the metastatic setting.
1. Background
Uterine sarcomas are rare. Together, they account for 3–9% of all
uterine cancers and the annual incidence is 0.36/100.000 woman-years
(Koivisto-Korander et al., 2012; Toro et al., 2006). Uterine sarcomas
(US) are classiﬁed into mesenchymal tumours or mixed epithelial and
mesenchymal tumours. Mesenchymal tumours are further classiﬁed as
uterine leiomyosarcoma (uLMS, 63%), endometrial stromal sarcoma
(ESS, 21%, usually divided into low grade (LG-ESS) and high grade
(HG-ESS)), adenosarcomas (AS, 5%), high grade undiﬀerentiated sar-
coma (HGUS, 5%) and other rare subtypes (e.g. alveolar or embryonal
rhabdomyosarcoma) (Trope et al., 2012; Abeler et al., 2009). Mixed
epithelial and mesenchymal tumours include uterine adenosarcomas
and carcinosarcomas (Hosh et al., 2016; Benson and Miah, 2017;
Nathenson et al., 2016). Adenosarcomas are mixed tumours with a
combination of a benign epithelial component and malignant me-
senchymal cells. The risk of relapse is markedly increased in case of
sarcomatous overgrowth (Nathenson et al., 2016). Carcinosarcomas,
also called malignant mixed Müllerian tumours, are generally regarded
of epithelial origin, and therefore are not part of this review. The pa-
thology of uterine sarcomas is known to be diﬃcult. In a population-
based study of uterine sarcomas from Norway 168 out of 419 (29%)
initially classiﬁed US were on review excluded or reclassiﬁed as for
example leiomyomas or leiomyoma variants according to the WHO
criteria (Abeler et al., 2009). Furthermore, the nomenclature has been
changed several times.
The clinical behaviour of the histological subtypes is diﬀerent.
Uterine leiomyosarcomas usually present as a bulky tumour in
women > 40 years with complaints of vaginal bleeding (56%), a
palpable pelvic mass (54%) and/or pelvic pain (22%) (Prat and
Mbatani, 2015). In a signiﬁcant part of the patients, the diagnosis is set
postoperative, instead of the expected leiomyoma(s). Distinction be-
tween leiomyoma and leiomyosarcoma is made with conventional
morphological criteria (mitosis, atypia and necrosis). The term STUMP
(smooth tumours of undeﬁned malignant potential) is used in a setting
when both leiomyoma as well as leiomyosarcoma cannot be diagnosed
with certainty. Uterine leiomyosarcoma are usually high grade with
typically a mitotic rate > 15/10 HPF. The prognosis of leiomyo-
sarcoma is poor, even when conﬁned to the uterus at the time of di-
agnosis. Recurrence rates are high; between 53 and 71%, and the
overall ﬁve-year survival rate is poor (Prat and Mbatani, 2015). In a
recent Surveillance Epidemiology and End Results (SEER) database
reporting of 13,089 US cases between 2000 and 2012, the ﬁve-year
relative survival for the group of uLMS patients was 42% (Hosh et al.,
2016). An earlier SEER paper reports a 5-year disease speciﬁc survival
per stage; stage I—76%, stage II—60%, stage III—45%, and stage
IV—29% (Kapp et al., 2008). In a Norwegian study, the ﬁve-year sur-
vival rate for uLMS was 51% for FIGO stage I and 25% for FIGO stage II,
whereas all patients with stage III–IV died within 5 years (Abeler et al.,
2009).
The term endometrial stromal tumour applies to neoplasms typi-
cally composed of cells that resemble endometrial stromal cells of the
proliferative endometrium. ESS are predominantly intramural neo-
plasms exhibiting myometrial invasion and permeation of myometrial
lymphovascular spaces. LG-ESS occurs in women between 40 and 55
years old of whom>50% is premenopausal. Patients can present with
vaginal bleeding, dysmenorrhoea or pelvic pain, but as many as 25% is
asymptomatic (Prat and Mbatani, 2015). Typically, hormone receptors
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(estrogen, progesterone) are positive on the tumour cells (Prat and
Mbatani, 2015). LG-ESS frequently have JAZF1 rearrangements (Huang
et al., 2004). Prognosis of LG-ESS is favourable. Recurrences occur in up
to one third of the patients and may occur after many years. Five-year
survival for stage I–II is 90%, compared to 50% for stage III–IV (Chan
et al., 2008). High grade ESS present with abdominal bleeding, an en-
larged uterus or pelvic mass at a mean age of 50 years (range 28–67).
The tumour may appear as intracavitary polypoid or mural masses. The
mitotic rate is> 10/10 HPF and estrogen and progesterone receptors
are negative (Prat and Mbatani, 2015). Recently, a t(10;17)(q22;p13)
translocation has been identiﬁed in a large proportion of high-grade
ESS. This rearrangement results in an in-frame fusion between YWHAE
(exons 1–5) and 1 of the 2 highly homologous genes FAM22A and
FAM22B (exons 2–7), formerly designated as YWHAE-FAM22 and
nowadays called YWHAE-NUTM2 (Lee et al., 2012a,b,c). The presence
YWHAE-NUTM2 helps to discriminate HG-ESS from the more common
low-grade ESS with JAZF1 rearrangement and from HGUS with no
identiﬁable molecular aberrations, which is important in guiding clin-
ical management (Lee et al., 2012a; Pautier et al., 2014). Cyclin D1 can
be used as an immunohistochemical diagnostic indicator for HG-ESS
with YWHAE-NUTM2 rearrangement (Chan et al., 2008). Compared to
LG-ESS, patients with HG-ESS more frequently encounter recurrences
and they occur earlier after primary diagnosis. In the SEER database,
ﬁve-year relative survival for all stage low grade and high grade ESS
together was 72.7% (Hosh et al., 2016).
Adenosarcomas are characterized by benign epithelial elements and
a malignant mesenchymal component. They most commonly present
with vaginal bleeding. Pathologic diagnosis is dependent on the iden-
tiﬁcation of the characteristic morphologic features. The most common
immunohistochemical markers for adenosarcoma are CD10 and WT1,
but these are not speciﬁc. High frequency of TP53 abnormalities has
been described in high grade AS (Hodgson et al., 2017). The majority of
patients present with stage I disease, with a 5-year overall survival of
60–80%. Survival is inﬂuenced by the presence of myometrial invasion,
sarcomatous overgrowth, lymphovascular invasion, necrosis, and the
presence of heterologous elements including rhabdomyoblastic diﬀer-
entiation. The reported prevalence of sarcomatous overgrowth in pa-
tients with uterine adenosarcoma varies greatly, from 8% to 65%
(Carroll et al., 2014). Patients with sarcomatous overgrowth have sig-
niﬁcantly increased risk of recurrence 23 versus 77% and decreased 5-
year overall survival 50–60% (Nathenson et al., 2016). Comparable
numbers have been reported in a National Cancer Database study, with
a ten years overall survival of approximately 60% in a cohort with 1137
uterine AS patients (Seagle et al., 2016).
HGUS are very rare and aggressive. They are poorly diﬀerentiated
sarcomas composed of cells that do not resemble proliferative-phase
endometrial stroma. HGUS are separated into uniform and pleomorphic
types. Uniform-type HGUS shows permeative myometrial involvement
with lymphovascular embolism and no destructive involvement of the
myometrium in contrast to pleomorphic undiﬀerentiated ESSs.
Uniform-type HGUS shows fusiform spindle cells or round cells.
Pleomorphic-type HGUS exhibits high-grade cytological atypia with
marked nuclear pleomorphism accompanied in most instances by a
high mitotic rate (almost always exceeding 10MF/10 HPF and some-
times approaching 50MF/10 HPF) and the presence of tumour necrosis.
HGUS is often heterogeneous and composed of diﬀerent components,
e.g. dediﬀerentiated ESS, dediﬀerentiated leiomyosarcomas, the sar-
comatous component of adenosarcomas or carcinosarcomas with
overgrowth of epithelial elements, etc. (Pautier et al., 2014). Approxi-
mately 60% of the patients present with stage III or IV disease. The
prognosis is very poor with a median survival, once metastasised of less
than a year (Prat and Mbatani, 2015; Tanner et al., 2012).
We here review the results of systemic treatment in uLMS and ESS in
the adjuvant and metastatic settings. The limited available data on AS
and HGUS will also be discussed.
2. Adjuvant treatment
As described above, the recurrence rates can be high and disease
speciﬁc survival may be low in some types of US, especially uLMS.
Important risk factors are high mitotic count, tumour spill and mor-
cellation of suspected benign leiomyoma which appear to be leiomyo-
sarcomas by pathology review afterwards. Several attempts have been
made to improve disease free survival by adding adjuvant therapy.
2.1. Hormonal therapy
Both uLMS and ESS can express estrogen receptors (ER) and/or
progesterone receptors (PR). For uLMS, ER expression has been re-
ported in 18–87% and PR expression in 18–80%. In ESS, ER expression
has been shown in 40–100% and PR expression 60–100% (Amant et al.,
2009). HGUS do not express hormone receptors. Adenosarcoma may
express both estrogen and progesterone receptors in both the epithelial
as well as sarcomatous component, although hormone receptor ex-
pression has not been seen in the sarcomatous part of tumours with
sarcomatous overgrowth (Amant et al., 2004). Conﬂicting data have
been published about the association between hormone receptor ex-
pression and prognosis (Davidson et al., 2016; Raspollini et al., 2003;
Garcia et al., 2015; Lusby et al., 2013; Koivisto-Korander et al., 2011;
Akhan et al., 2005; Leitao et al., 2012; Ioﬀe et al., 2009).
There are no prospective randomized controlled studies of hormonal
therapy in uterine sarcomas, neither in the adjuvant nor in the meta-
static setting (Thanopoulou and Judson, 2012). We here summarize the
outcome of series of at least ten patients or more.
2.1.1. ESS
In a retrospective series, four out of thirteen ESS patients who re-
ceived progestins as adjuvant therapy recurred compared with 6 of 9
ESS patients who did not receive adjuvant progestins (31% vs. 67%)
(Chu et al., 2003). Another retrospective series reports the results of
adjuvant hormonal therapy (mainly megestrol acetate or medrox-
yprogesterone) in thirty low grade ESS patients. The median overall
survival with hormonal therapy was 94 months in the patients with
adjuvant hormonal therapy versus 72months in the observation cohort
(p= .07) (Leath et al., 2007). Cheng et al. (2011) reported a series of 25
low grade ESS who had a median time to progression after adjuvant
hormonal therapy of 132 months. In 10 FIGO stage I–II ESS patients
treated with adjuvant hormonal therapy (megestrol acetate of ar-
omatase inhibitors), no relapse occurred. Patients were treated between
1977 and 2007 and the results were reported in 2010, without men-
tioning the median follow up time (Malouf et al., 2010). In a Chinese
retrospective series, 11 out of 114 low grade ESS received some form of
adjuvant hormonal therapy. Disease free survival did not diﬀer from
patients without or another type of adjuvant treatment and no other
details are available (Zhou et al., 2015). Finally, Amant et al. reported
the results of adjuvant hormonal treatment, deﬁned as a minimum of
200mg medroxyprogesterone acetate, in 2 out of 22 (9%) and 5 out of 9
(56%) of ESS patients with stages I and III–IV, respectively. Among
stage I women receiving adjuvant hormonal treatment or not, 0 out of 2
(0%) and 4 out of 20 (20%) relapsed. And among stages III–IV women
receiving adjuvant hormonal treatment or not, 1 out of 5 (20%) and 3
out of 4 (75%) relapsed (Amant et al., 2007). All together, there is no
evidence to support the use of adjuvant hormonal therapy as standard
of care in ESS.
2.1.2. uLMS
Even less data is available for uLMS and the use of adjuvant hor-
monal treatment. The results of recently ﬁnished randomized phase II
study of letrozole versus observation in patients with newly diagnosed
uLMS limited to the uterus with at least 10% estrogen receptor ex-
pression [NCT00414076] are awaited.
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2.1.3. HGUS and adenosarcoma
There is no literature about adjuvant hormonal therapy in HGUS
and adenosarcomas. This makes sense since the lack of hormone re-
ceptor expression in HGUS. In adenosarcomas, hormone receptor ex-
pression has been reported, but we did not found any (adjuvant or
palliative) trials or series of ten or more patients treated with hormonal
therapy (Amant et al., 2004). However, the other way around, adeno-
sarcomas have been associated with tamoxifen use in breast cancer
(Clement et al., 1996).
2.2. Adjuvant chemotherapy in US
Only a few prospective studies with adjuvant chemotherapy have
been performed and these are summarized in Table 1 (Omura et al.,
1985; Hensley et al., 2013, 2009a; Hempling et al., 1995). The popu-
lations of these studies were mixed, including also carcinosarcomas,
and had small numbers. These prospective results do not support ad-
juvant treatment so far. However, it is encouraging that in a single arm
phase II study of 47 high grade uLMS patients treated with 4 cycles of
gemcitabine-docetaxel followed by 4 cycles of doxorubicin, the median
PFS was not yet reached after a median of 39.8 months of follow up
(Hensley et al., 2013).
To date four retrospective series in US have been reported with at
least one chemotherapy containing arm. The largest series is an ob-
servational cohort study of the National Cancer Database in FIGO stage
I ESSS. Out of 2414 women with LG- ESS, 4.8% (n=115) received
adjuvant chemotherapy. Approximately one-third (33.4%, 444/1383)
of women with HG-ESS received primary adjuvant chemotherapy, and
of these women 75.9% (337/444) received multi-agent chemotherapy.
Use of adjuvant chemotherapy and radiotherapy was associated with
increased survival for HG- ESS, but not in LG-ESS (Seagle et al., 2017).
A second retrospective study in 108 high grade stage I–II uLMS patients
comparing adjuvant chemotherapy to radiotherapy or observation did
also report no clinical beneﬁt of any adjuvant treatment (Ricci et al.,
2013). The same was the case in a very recent retrospective series of
111 stage I uLMS patients of whom 33 patients received a median of 4
cycles of gemcitabine-docetaxel, without survival beneﬁt (Littell et al.,
2017). The fourth study by Roque et al. presented a retrospective series
of 56 uLMS patients treated with chemotherapy (30 gemcitabine-doc-
etaxel, 26 other) compared to radiotherapy (n= 41) and observation
(n= 31). There was no diﬀerence in PFS or OS in women with uLMS
treated with adjuvant gemcitabine-docetaxel versus those who were
observed or received irradiation alone or a chemotherapy regimen
other than gemcitabine-docetaxel (Roque et al., 2016).
In July 2016, a systematic review and meta analysis was published.
Of 360 early stage uLMS patients included, 40% received adjuvant
chemotherapy (with or without radiotherapy). These patients were
compared to radiotherapy alone or observation (53 and 155 patients).
Chemotherapy did not prove to be of beneﬁt in terms of local or distant
recurrence rate (Bogani et al., 2016).
Prospective randomized trials are desperately needed in this disease
with high relapse risk. Unfortunately, the Gynaecologic Oncology
Group (GOG) 277 phase III trial comparing 4 cycles of gemcitabine-
docetaxel followed by 4 cycles of doxorubicin versus observation in
high risk uLMS was closed prematurely due to poor accrual
[NCT01533207]. One of the important reasons of the diﬃculty in
running this study was the diﬀerence between the intensive treatment
arm with 8 cycles of chemotherapy and an observation only arm. Also,
for patients just recovering from surgical procedures the prospect of 8
cycles of chemotherapy could be felt quite challenging.
The lack of a universally recognised standard chemotherapy com-
parator arm, continues to hamper the development of future rando-
mised clinical trials in this setting. Currently the general perception is
that there is no routine role for adjuvant therapy, although in practice it
may be oﬀered in cases where tumour morcellation took place and
other indications with obvious tumour spill during surgical removal ofTa
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the tumour.
2.3. Adjuvant radiotherapy alone
Only one prospective trial in early stage (I–II) US is available.
Adjuvant radiotherapy was compared to observation and did not result
in an improvement of local control, the rate of distant metastases, or OS
(Reed et al., 2008). Furthermore, a recent report of the SEER database
even concluded that (retrospectively) survival was worse in patient
treated with surgery and adjuvant radiotherapy compared to surgery
alone (Hosh et al., 2016). Therefore, there is no routine role for
radiotherapy in this setting.
2.4. Combined radiotherapy and chemotherapy
In the SARCGYN trial, 81 patients with FIGO stage≤ III US (11%
HGUS, including carcinosarcomas) were treated with four cycles of
doxorubicin 50mg/m2 d1, ifosfamide 3 g/m2, d1-2, cisplatin 75mg/m2
d3, (API) and G-CSF q 21 days followed by radiotherapy compared to
radiotherapy alone. This study was closed prematurely because of poor
accrual. The 3-year disease free survival rates were 55 vs. 41%
(p= .048), respectively, but without improvement of the 3-year OS (81
vs 69%, p= .41), respectively. Toxicity was high with grade 3–4 toxi-
city (mainly bone marrow suppression) in up to 76% of patients and
two toxic deaths due to febrile neutropenia.
2.5. Conclusion—adjuvant setting
Currently, there is neither prospective, nor retrospective, evidence
in favour of adjuvant treatment for uterine sarcomas. However, expert
opinions mention the possibility to consider adjuvant therapy in se-
lected cases with high risk US. On individual base, for hormone re-
ceptor positive HG-ESS hormonal therapy might be considered, care-
fully balancing the unproven eﬃcacy versus the possible negative
eﬀects. Because of its good prognosis, adjuvant hormonal therapy in
LG-ESS is not clinically meaningful. For uLMS, adjuvant chemotherapy
(e.g. 4–6 cycles of doxorubicin or gemcitabine-docetaxel) might be
considered in younger and otherwise healthy patients with a high risk
on recurrence (e.g. high grade, tumour spillage or morcellation), after
discussion in a multidisciplinary sarcoma tumour board. For HGUS,
unfortunately, no conclusion can be made with the unfortunate pre-
mature closure of the phase III study.
3. Metastatic treatment
3.1. Hormonal therapy
3.1.1. ESS
Again, only case reports and small retrospective series are available.
We here discuss series of at least 10 patients. The Royal Marsden
Hospital single experience observed objective response in 46.2% and
clinical beneﬁt in 92.4% in 13 metastatic ESS patients treated with ﬁrst
line hormonal therapy. Aromatase inhibitors were prescribed as ﬁrst
endocrine line in 11 out 13 patients and progestins in the remainder,
while in second line treatment other aromatase inhibitors were pre-
scribed in 7 out of 10 patients, followed by progestins and GnRH ana-
logues. Median PFS for ﬁrst line was 4.0 years, with a 5-year PFS rate of
30.8%. Median PFS for second line hormonal treatment was 3.0 years,
with a 2-year PFS rate of 88.9% (95% CI: 68.3–100.0) (Thanopoulou
et al., 2015). A Dutch series of 11 LG-ESS patients with residual or
recurrent disease treated with megestrol acetate or aromatase in-
hibitors, observed in 9 (82%) patients an objective response (4 com-
plete responses; 5 partial responses). The response duration ranged
from 4 to 252 months (median 48 months) (Dahhan et al., 2009). Ioﬀe
et al. (2009) reported stable disease, complete or partial response in 14
of 18 ESS patients with recurrent or progressive disease who were
treated with hormonal therapy (range of follow up: 6–124 months).
In second line, only case reports are available (Shoji et al., 2011;
Nakamura et al., 2016).
Importantly, all case series are small and retrospective, and the
natural behaviour of ESS can be indolent.
3.1.2. uLMS
Only one prospective phase II trial with letrozole has been per-
formed in 27 ER and/or PR positive uLMS patients with a median of 2
prior lines of systemic therapy. The median PFS was 12 weeks. The best
response was stable disease in 14 patients (54%). Three patients, all
with tumours expressing ER and PR in >90% of tumour cells, con-
tinued to receive letrozole for > 24 weeks. Median duration of therapy
for the study population was 10 weeks. The most common reason for
treatment discontinuation was disease progression (85%) (George et al.,
2014). In a retrospective series with sixteen patients with measurable
advanced uLMS, patients were treated with an aromatase inhibitor (ﬁrst
line mainly letrozole, second line mainly exemestane). Median PFS in
ﬁrst line was 14 months, and prolonged PFS was more likely to be
observed in patients with low grade compared to high grade ULMS (20
months vs. 11 months), and in moderate strong ER positive compared
to weak ER positive ULMS (20 months vs. 12 months). Best response
was a partial response in 2 out of 16 patients (12.5%) and the clinical
beneﬁt rate, deﬁned as complete response plus partial response plus
stable disease ≥6 months, was observed in 10 out of 16 patients
(62.5%). Median duration of second line was 3 months and median PFS
was not reached. The 1-year PFS rate for the second line aromatase
inhibitor was 80% (Thanopoulou et al., 2014). The Memorial Sloan-
Kettering Cancer Centre presented their experience in 34 advanced or
recurrent uLMS patients (65% ER+, 29% PR+) treated with aromatase
inhibitors. Median PFS was 2.9 months and best objective response was
partial response in 3 out of 34 patients (9%) (all of whom were ER
positive). In the subgroup with ER or PR positive uLMS, the 1 year
progression free survival rate was 28% (O’Cearbhaill et al., 2010).
3.1.3. Conclusion hormonal therapy—metastatic setting
Although prospective evidence is scarce, the series presented do
show that in selected cases (e.g. ER and/or PR positive, low grade, low
volume disease) hormonal therapy can be attractive in stabilising dis-
ease and ultimately postponing chemotherapy. This is more the case in
ESS than in uLMS. In the majority of patients, hormonal therapy has the
advantage of being well tolerated and less toxic than systemic che-
motherapy. However, almost all presented data are retrospective. A
selection and publication bias must be considered and there is a lack of
systematic analysis of the hormone receptor status. The lack of avail-
able data of control patients makes it diﬃcult to interpret the results of
the observations as discussed. Objective radiological response is the
most convincing indication of eﬃcacy of treatment in these un-
controlled studies and case series.
3.2. Chemotherapy in US
Despite many eﬀorts, the 5-years disease speciﬁc survival for all
types of locally advanced and metastatic US (including carcino-
sarcomas) did not improve in the past decennium (Hosh et al., 2016;
Kapp et al., 2008). Multiple prospective trials with palliative che-
motherapy have been done (Table 2). They encompass the whole range,
from smaller studies in uLMS only to larger soft tissue sarcoma (STS)
trials including also uterine sarcoma or leiomyosarcoma patients of
non-uterine origin. Due to its rarity and its more indolent behaviour,
only small numbers of ESS and HGUS patients have been included in
STS trials. Furthermore, one must consider that part of the prospective
trials and all of the retrospective series have been done without central
pathology review and that up to 30% of the pathological diagnosis may
be wrong (Abeler et al., 2009).
The National Cancer Database of the United States concluded that
I.M.E. Desar et al. Critical Reviews in Oncology / Hematology 122 (2018) 10–20
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chemotherapy adds 8.5 months beneﬁt compared to untreated patients
with metastatic uLMS (19.4 vs. 10.9 months) in an observational cohort
study of patients diagnosed between 1998 and 2013 (Seagle et al.,
2017). Recently, a pooled analysis of 269 metastasised US patients
treated within 13 trials (total 3270 STS patients) of the EORTC Soft
Tissue and bone Sarcoma has been published (Ray-Coquard et al.,
2016). Median OS was 10.4 months, median PFS 4.1 months. Four
categories of chemotherapy were evaluated; anthracyclines alone,
ifosfamide alone, combined doxorubicin-ifosfamide and the combina-
tion of cyclophosphamide, doxorubicin, vincristine and dacarbazine
(CYVADIC). Clinical outcome was not inﬂuenced by category of che-
motherapy. Histological subtypes were grouped as LMS versus others.
Lower response rates were observed in LMS (19 versus other 33%) and
the response for ifosfamide as single agent was only 5% for al US.
Gemcitabine-docetaxel was not part of this analysis.
In Table 2 we summarize the prospective trials with palliative
chemotherapy in US or STS trials important for the nowadays insights
in the standard of care for STS in general including US. Where avail-
able, numbers of (u)LMS within general STS trials have been provided.
The majority of the studies had negative results and did not improve the
survival of patients with advanced or metastatic uterine sarcomas. We
here discuss the prospective trials summarized in Table 2.
3.2.1. Eﬃcacy of chemotherapy in ﬁrst line
As in other soft tissue sarcomas, doxorubicin is still the ﬁrst line
treatment in uterine sarcomas. Mainly all ﬁrst line trials in US or (u)
LMS were doxorubin based or used gemcitabine-docetaxel (Seddon
et al., 2015; Hensley et al., 2015, 2002, 2008b; Long et al., 2005;
Edmonson et al., 2002; Pautier et al., 2012). For a long time, it was
debated whether single agent doxorubicin or the combination of gem-
citabine-docetaxel was best in (u)LMS. Recently, the results of the UK
GeDDiS Phase III trial have been published. This trial included 257
patients with STS who were randomized between doxorubicin 75mg/
m2 q 21 days or the combination of gemcitabine 650mg/m2 Day 1 and
8, q21 days and docetaxel 75mg/m2 every 21 days. No signiﬁcant
diﬀerence in median PFS (23.3 and 23.7 weeks) or median OS (76.3 vs.
76.3 weeks) for doxorubicin versus gemcitabine-docetaxel was reported
and response rates of 20 and 19% for both treatment arms. Further
subgroup analyses were done comparing leiomyosarcoma versus other
sarcomas (p= .14), and uterine leiomyosarcoma versus other sarcomas
(p= .38), but again no diﬀerential eﬀect was evident between the two
treatment groups (Seddon et al., 2017). The authors concluded that
single agent doxorubicin is still the preferred ﬁrst line treatment in STS
and the results in the (u)LMS cohort do not support other preferences.
The addition of olaratumab to doxorubicin showed an impressive im-
provement of OS compared to doxorubicin alone in the Phase Ib-II trial
(26.5 vs. 14.7 months) in unselected STS but needs conﬁrmation in a
Phase III trial, which has recently completed accrual and results are
expected around 2019–2020 (Tap et al., 2016) [NCT02451943]. In
those STS patients in need for a volume response (e.g. induction therapy
or because of palliative reasons) the combination of doxorubicin and
ifosfamide is recommended (Judson et al., 2014). However, the Eur-
opean Society of Medical Oncology (ESMO) guidelines suggests the
combination of doxorubicin-dacarbazine (Antman et al., 1993; Omura
et al., 1983). instead of doxorubicin combined with ifosfamide in case
combination therapy is warranted, since the activity of ifosfamide is
limited in uterine leiomyosarcomas (Ray-Coquard et al., 2016; Antman
et al., 1993; Casali et al., 2014). Anthracycline based combination
therapy in ﬁrst line palliative treatment is considered to be more toxic
and should be reserved for patients in need for a volume response, e.g.
in case of severe symptoms.
Based on an encouraging objective response rate of 60% in the
uLMS subgroup treated with the combination of doxorubicin and tra-
bectedin in a non-randomised phase II trial (Pautier et al., 2015), a
phase III trial; combining doxorubicin plus trabectedin versus doxor-
ubicin followed by trabectedin in uterine or soft tissue leiomyosarcomaTa
bl
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patients is currently in preparation [NCT02997358]. Recently, a ran-
domised phase II study of Martin-Broto et al. (2016) with the same
combination in STS patients versus doxorubicin was closed because of
futility after interim analysis.
3.2.2. Eﬃcacy of chemotherapy after failure of the ﬁrst line
Multiple trials have been performed in second line and further. The
results are summarized in Table 2. Proportions of (u)LMS patients in US
or STS trials have been mentioned but should be interpreted with
caution since these trials were not powered for subgroup analyses. The
results do not warrant a diﬀerent approach for uterine sarcomas as for
STS in general, although details may be slightly diﬀerent. Again, ifos-
famide is less frequently used in (u)LMS both in ﬁrst as well as in
second line (Ray-Coquard et al., 2016). Trabectedin (Pautier et al.,
2015; Demetri et al., 2016) and dacarbazine (Garcia-Del-Muro et al.,
2011; Schoﬀski et al., 2016) are the most frequently used drugs. A di-
rect comparison has been made in a phase III trial with trabectedin vs.
dacarbazine in patients with leiomyosarcomas and liposarcomas in
third line and further (Demetri et al., 2016). A total of 518 patients
were enrolled and randomly assigned to either trabectedin (n=345) or
dacarbazine (n= 173). Median PFS for trabectedin vs. dacarbazine was
4.2 vs. 1.5 months; hazard ratio, 0.55; P < .001). In the pre-deﬁned
sub-analyses all subgroups beneﬁted from trabectedin, although the
beneﬁt was not statistically signiﬁcant in all these subgroups. The in-
terim analysis of OS (64% censored) demonstrated a non-signiﬁcant
13% reduction in risk of death in the trabectedin arm compared with
dacarbazine (median OS for trabectedin v dacarbazine, 12.4 v 12.9
months; hazard ratio, 0.87; P= .37). In a post hoc subset analysis of the
uLMS cohort of this trial, trabectedin treatment resulted in signiﬁcantly
longer PFS versus dacarbazine (4.0 vs. 1.5 months), without diﬀerence
in OS (14.4 vs. 12.9 months). Objective response rate was 11% with
trabectedin vs. 9% with dacarbazine (P= .82) and clinical beneﬁt rate
for trabectedin was 31% vs. 18% with dacarbazine (P= .05) (Hensley
et al., 2017).
Despite the negative results for leiomyosarcoma in the recently
published phase IIII eribulin trial, the results of the comparator da-
carbazine arm are interesting (Schoﬀski et al., 2016). A total of 452
patients with intermediate-grade or high-grade advanced liposarcoma
or leiomyosarcoma (28–30% uLMS) who had received at least two
previous systemic regimens for advanced disease (including an an-
thracycline) were 1:1 randomized to eribulin mesilate or dacarbazine
(850–1200mg/m2 intravenously on Day 1) every 21 days until disease
progression. OS was signiﬁcantly improved in patients assigned to
eribulin compared with those assigned to dacarbazine (median OS 13.5
vs. 11.5 months; hazard ratio 0.77). This OS beneﬁt was only seen in
liposarcoma patients (median OS 15.6 months vs. 8.4 months, respec-
tively) and not in those with leiomyosarcoma (12.7 vs. 13.0 months).
Median PFS was similar in both treatment groups: 2.6 months. Re-
markably, this trial conﬁrms the activity of dacarbazine in leiomyo-
sarcoma by its relatively long survival of LMS patients who were in-
cluded in a third line or higher trial. Temozolomide, the prodrug of
dacarbazine, had been reported to induce some (partly prolonged)
responses in a retrospective series of in total 19 patients (Anderson and
Aghajanian, 2005).
Due to its rarity, the data on chemotherapy in metastatic ESS are
sparse. For both ESS and HGUS, no speciﬁc conclusions can be with-
drawn because of a lack of evidence.
3.2.3. Conclusion chemotherapy—metastatic setting
Most trials focused on STS or (u)LMS, and rarely include patients
with ESS or HGUS. By evidence and eﬃcacy, ﬁrst line treatment of
choice still remains doxorubicin (+/− olaratumab if available) or
perhaps doxorubicin-dacarbazine in case of the need of combination
therapy. Within the next few years, the results of the ongoing phase III
trials may (or may not) change this into doxorubin-olaratumab or
maybe doxorubicin-trabectedin. After ﬁrst line therapy, many drugs
have some activity but in general the prognosis remains poor. Choice of
treatment in this setting includes consideration of toxicity proﬁle and
patient preference. Trabectedin, dacarbazine and gemcitabine based
chemotherapy are active options. Clinical trial options should always be
considered.
3.3. Other, non cytotoxic, systemic therapy in second line and further
Many cancer patients beneﬁt from the big breakthroughs of the past
few years, such as immunotherapy and targeted therapy. Unfortunately,
this is not the case for uterine sarcomas.
3.3.1. Immunotherapy
Only a limited number of studies have been performed to assess
eﬃcacy in uterine sarcomas (Table 3). Uterine LMS exhibit moderate
immunohistochemical expression of PD1 (46.9%) and PDL1 (36%)
(Herzog et al., 2015). Only one phase II trial and only one case report
on immunotherapy in uterine sarcomas have been published so far
(George et al., 2017; Ben-Ami et al., 2017). In twelve uLMS patients
treated with PD-1 inhibitor nivolumab 3mg/kg every two weeks, no
objective responses where found and median PFS was only 1.8 months.
Due to a lack of clinical beneﬁt the second part of the study wasn’t
opened. Archival samples were available for 83% of patients. PD-1
(> 3% of cells), PD-L1, and PD-L2 (> 5% and>10% of tumour cells,
respectively) expression were observed in 20%, 20%, and 90% of
samples, respectively (Ben-Ami et al., 2017). Very recently, a phase II
trial testing nivolumab in all types of uterine cancer, including uLMS,
HG-ESS and HGUS, started recruitment (NCT03241745).
Other ongoing immunotherapy studies are not speciﬁcally focused
on uterine sarcomas. An active phase II study is investigating the role of
the anti-PD-1 antibody, pembrolizumab, in patients with advanced soft
tissue and bone sarcomas (NCT02301039). Furthermore, a phase I–II
trial combining pembrolizumab with doxorubicin in advanced or me-
tastatic STS is open (NCT02888665), as is a phase II study of
Talimogene Laherparepvec (T-VEC) combined with pembrolizumab
(NCT03069378). In the neoadjuvant setting, anti-PD-L1 (Durvalumab/
MEDI4736) plus anti-CTLA-4 (Tremelimumab) and radiation is tested
for high risk STS (NCT03116529). The combination of tyrosine kinase
Table 3
Systemic non-cytotoxic treatment trials in advanced or metastastic uterine sarcomas.
population n (%(u)LMS) RR (%) 3mo PFR (%) 6mo PFR (%) PFS (months) OS (months)
nivolumab (Ben-Ami et al., 2017) uLMS 12 0 – – 1.8 –
pazopanib (Benson et al., 2016) US 44 11 – – 3 17.5
regorafenib vs. placebo (Mir et al., 2016) STS, 1 cohort LMS 56 LMS of who 22 uLMS 0 57 vs. 25 21 vs. 7 3.7 vs. 1.8 21 vs. 9.1
sunitinib (Hensley et al., 2009b) uLMS 23 8.7 – 17.4 1.5 15.1
thalidomide (McMeekin et al., 2007) uLMS 30 0 – – 1.9 8.3
aﬂibercept (Mackay et al., 2012) uLMS 41 0 – 17 1.8 18.1
alisertib (Hyman et al., 2017) uLMS 21 0 0 1.7 14.5
M; median, mo; months, RR; response rate, PFS; progression free survival, OS; overall survival, US; uterine sarcomas, uLMS; uterine leimyosarcoma, LMS; leiomyosarcoma, STS; soft tissue
sarcoma.
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inhibitor axitinib and pembrolizumab is currently tested in speciﬁc
types of STS, including LMS after failure of anthracyclines
(NCT02636725). As a ﬁrst line therapy, the combination of trabectedin,
nivolumab and anti-CTLA-4 ipilimumab is under investigation in a dose
ﬁnding phase I–II study for advanced STS (NCT03138161).
3.3.2. Targeted therapy
Targeted therapy refers to systemic therapy directed to speciﬁc
elements or pathways crucial for cancer cells to survive. Only results of
a few trials or subgroup analyses in uterine sarcomas are available
(Table 3). Some categories of targeted therapy can be distinguished:
3.3.2.1. Tyrosine kinase inhibitors directed against a.o. vascular endothelial
growth factor receptor (VEGFR) and platelet derived growth factor receptor
(PDGFR). A subgroup analysis on 34 patients with uterine sarcomas
treated the phase II pazopanib trial or PALETTE trial showed a response
rate of 11%, median PFS of 3.0 months and OS of 11.1 month, which
was worse compared to the non uterine STS types (mPFS 4.5 months,
mOS 17.5 months) (Benson et al., 2016). A randomized phase II study
comparing pazopanib combined with gemcitabine to gemcitabine-
docetaxel in STS is currently ongoing (NCT01593748). Sunitinib
50mg OD 4 weeks on–2 weeks of, failed to achieve a suﬃcient
number of objective responses (8.7%) or sustained disease
stabilization (mPFS 1.5 months and 6 months PFS rate 17.4%) as
second- or third-line treatment for uterine leiomyosarcoma (Hensley
et al., 2009b). Cabozantinib, targeting MET as well as VEGFR, is
currently under investigation as maintenance therapy after
chemotherapy in metastatic HGUS, adenosarcomas, and HG ESS
(NCT01979393).
3.3.2.2. VEGF trap/antibody. VEGF trap aﬂibercept 4mg/kg iv every 2
weeks showed similar disappointing results in patients with uLMS or
carcinosarcomas of the uterus: no objective responses were observed,
median PFS was 1.8 months and the 6 months PFS was 17% (Mackay
et al., 2012). The addition of VEGF antibody bevacizumab to
gemcitabine-docetaxel did not improve outcome (Hensley et al., 2015).
3.3.2.3. PDGFR antibody. As described above, in a randomized phase II
trial, addition of PDGFR antibody olaratumab improved OS by more
than 10 months (Tap et al., 2016). The phase III trial is ongoing
[NCT02451943]. Currently, the addition of olaratumab to gemcitabine-
docetaxel is investigated in a phase Ib-II trial in STS (NCT02659020).
3.3.2.4. Other targets. Although the PI3K/mTOR pathway has been
recognised as a potential target for uLMS in preclinical work, no series
or (ongoing) trials have been found for US (Cuppens et al., 2017a). The
same is the case for VIPR2, a gene aﬀected in 96% of 84 uLMS samples
which seems to act as a tumour suppressor gene (Cuppens et al.,
2017b).
3.3.2.5. Epigenetic modulators. Histone deacetylase inhibitor
panobinostat in a phase II trial for STS with 10 LMS and 3 ESS
patients did not result in any objective responses but 2/10 LMS and 2/3
ESS patients had prolonged stable disease for more than six months.
Pabinostat was poorly tolerated with the need of dose reduction in up to
one third of the patients due to thrombocytopenia, anaemia,
lymphocytopenia, fatigue and QTc prolongation (Cassier et al., 2013).
Aurora A kinase inhibitor alisertib was not eﬀective in 21 uLMS patient
as no objective responses or prolonged stable disease were seen. Median
PFS and OS were 1.7 and 14.5months, respectively (Hyman et al.,
2017).
In conclusion, currently, with respect to targeted agents, only pa-
zopanib has a place in the treatment of US after failure of at least an-
thracyclines. Based on promising phase II results and awaiting the
outcome of the phase III study, in some countries olaratumab can be
added to doxorubicin in ﬁrst line treatment.
4. Future directions and conclusion
Uterine sarcomas encompass a rare group of diseases with a dismal
prognosis of aggressive subtypes. For the choice of systemic treatments,
part of the diﬃculty is the recognition of the speciﬁc subtype of uterine
sarcoma and an adequate pathology diagnosis, including molecular
analyses. Very recently, new genetic and immunological diﬀerences
between uLMS, ESS and HGUS were shown. Gene expression and im-
munohistochemical analyses revealed the presence of high numbers of
tumour-associated macrophages (TAMs) in HGUS, which makes HGUS
patients suitable candidates for therapies targeting TAMs. Furthermore,
a high genomic instability of HGUS and downregulation of several
TP53-mediated tumour suppressor genes, such as NDN, CDH11, and
NDRG4 were proven. Moreover, it was demonstrated that HGUS carry
somatic mutations in several oncogenes and tumour suppressor genes
implicated in RAS/PI3K/AKT/mTOR, ERBB3, and Hedgehog signaling
for which targeted therapies exist (Przybyl et al., 2017).
After the primary diagnosis and treatment by gynaecologists and
their multidisciplinary teams, early involvement of sarcoma specialists
is necessary. Many centres are only treating a few patients per year. All
together, this makes it diﬃcult to improve the diagnostic and treatment
trajectory of US patients. Centralisation of care and the timely colla-
boration between gynaecological oncologists and sarcoma specialists
might help to deliver the best knowledge, experience and trial avail-
ability to US patients. By now, despite many attempts to improve the
outcome by systemic treatments, the prognosis, both after primary di-
agnosis and in case of metastatic disease, remains poor. The observation
of heterogeneity within uterine sarcoma subtypes warrants a persona-
lised treatment approach. Further studies with realistic analysis of pa-
tients numbers are needed to improve patient outcome. Given the ex-
periences so far, this is a challenge at a global level.
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